



**HAL**  
open science

## Encapsulation of bioactive compounds: Role of nanotechnology

Narimane Lammari, Hadjira Rabti, Ouahida Louaer, Abdelhamid Elaïssari,  
Abdeslam Hassen Meniai

► **To cite this version:**

Narimane Lammari, Hadjira Rabti, Ouahida Louaer, Abdelhamid Elaïssari, Abdeslam Hassen Meniai. Encapsulation of bioactive compounds: Role of nanotechnology. Principles of Biomaterials Encapsulation: Volume One, Elsevier, pp.39-65, 2023, Woodhead Publishing Series in Biomaterials, 10.1016/B978-0-323-85947-9.00007-8 . hal-03996452

**HAL Id: hal-03996452**

**<https://hal.science/hal-03996452>**

Submitted on 9 Nov 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# CHAPTER 3

## Chapter Title:

Encapsulation of bioactive compounds: Role of nanotechnology

## Author Name/s:

Narimane Lammari<sup>1</sup>, Hadjira Rabti<sup>1</sup>, Ouahida Louaer<sup>1</sup>, Abdelhamid Elaissari<sup>2</sup>, Abdeslam Hassen Meniai<sup>1,\*</sup>

## Author Affiliation/s:

<sup>1</sup> Environmental Process Engineering Laboratory, University Constantine 3, Salah Boubnider, Constantine, Algeria.

<sup>2</sup> Univ Lyon, University Claude Bernard Lyon-1, CNRS, ISA-UMR 5280, 69622 Villeurbanne, France.

\* **Corresponding Author:** Abdeslam Hassen Meniai (meniai@yahoo.fr)

## Abstract

Tissue engineering and regenerative medicine, one of the most exciting and emerging fields in the last decade, aim to maintain, restore or improve tissues and thus organ functions. Nanomaterials have attracting unprecedented interest to be applied for such purposes owing to their particular features including biocompatibility, mechanical, optical, electrical, magnetic and catalytic characteristics compared to conventional systems. Nanomaterials have been proved as promising candidates to serve as a carrier system for delivery of growth factors, genes cytokines etc., to control properties of the scaffolds and also to provide contrast for cell imaging. These nanosystems can be made of polymeric, lipid or inorganic materials. In this review paper, the different types of nanomaterials used in tissue engineering and regenerative medicine along with their applications will be covered and discussed.

## Key words

Tissue engineering, regenerative medicine, nanomaterials.

## 3.1 Introduction

Tissue engineering and regenerative medicine are among the fastest evolving interdisciplinary fields in healthcare research aiming to regenerate or replace human cells, tissues or organs enabling to restore or establish normal function (Engel *et al.*, 2007). They have brought high expectations for a great number of current worldwide human health problems like cardiovascular and metabolic diseases, brain and spinal cord injuries, cancer, as well as organ failure (Lee and Walsh, 2016; Anthony and Borlongan, 2017; Curtin, Castaño and O'Brien, 2017; RaquelCosta-Almeida, Reis and Gomes, 2019). The so-called triad of tissue engineering therapies comprises the following essential components: stem cells, biomaterial scaffolds and signaling molecules (Liao, Chan and Ramakrishna, 2008). Commonly, a tissue engineering therapy consists on seeding stem cells over or into porous and biodegradable


biomaterial scaffold, before its implantation, in the aim of restoring a tissue function and/or repopulating a defect site (Dvir *et al.*, 2011). To date, some regenerative medicine products, comprising tissue-engineered biomaterials, scaffolds, implantable devices and cell-based therapies have been applied in clinical trials for diabetes, immune and inflammatory diseases. Unfortunately, the clinical applications of a wide variety of products have been challenged by several scientific and engineering problems such as the biomanufacturing of stem cells or tissues (inability of cells to self-assemble into 3D tissues, effective delivery and instability), the efficacy of biomaterial scaffolds (absence of cellular adhesion and limited ability to fully differentiate transplanted stem cells), the control of micro-environmental signals, the enzymatic degradation of bioactive molecules and the assessment of the efficacy of therapies (Gao *et al.*, 2015). Nanotechnology, despite its immense popularity in biologically-related fields, has been utilized in the field of tissue engineering and regenerative medicine thanks to its promising perspectives to manage these challenges. For instance, the nanomaterials structures are able to control cellular functions like adhesion, differentiation and proliferation. Secondly, the sustained release property and the possibility of functionalizing nanomaterials improve the efficacy of the treatment and reduce the undesirable effects. Furthermore, the nanomaterials, due to their unique optical and magnetic characteristics, are promising contrast agents for monitoring cellular behavior *in vivo* (Santo, Gomes, *et al.*, 2012; Gao *et al.*, 2015; Monteiro *et al.*, 2015; Mostafavi *et al.*, 2020). To substantiate these points, a plethora of research has been investigated, in the last decade, on the applications of nanotechnology in tissue engineering research. It was demonstrated that the fetal bovine serum-loaded liposomes incorporated in poly (2-hydroxyethyl methacrylate) scaffolds significantly improved both chondrocyte adhesion and proliferation (Rampichova, 2012). Similarly, Ertan *et al.* revealed that the conjugation of insulin-like growth factor I and transform growth factor b1 loaded poly(N-isopropylacrylamide nanoparticles with poly (lactic acid-co-glycolic) acid scaffolds provided more expression of collagen type II and aggrecan than those containing free or single growth factors (Ertan *et al.*, 2013). In addition, ultrasmall paramagnetic iron oxide particles were found efficient in visualizing and tracking human mesenchymal stem cells for up to 14 days after transplantation at injection sites (Mathiasen *et al.*, 2019).

This chapter highlights the very recent advancements in the development of different kinds of nanomaterials (including polymeric, lipid and inorganic materials) combined with biomaterial scaffolds of a specific tissue required for translatable regenerative medicine. Moreover, an overview of the existing technologies for tissue engineering are summarized and discussed.

## 3.2 Nanomaterials

A nanomaterial is a natural, incidental or manufactured material composed of particles in an unbound, aggregate or agglomerate state, in the nanometer size range (50% or more of the particles should be in a size distribution range from 1 to 100 nm) (Y. Sun *et al.*, 2020). In the last decade, nanomaterials offer an enormous outlook for promoting current therapies due to their particular benefits including targeted drug delivery, reduced side effects, lowered drug concentrations, and increased patient compliance. Nowadays, these systems emerged new treatment tools for tissue engineering therapies and regenerative medicine because of their

unique physical and chemical features (Nemeth, Fine and Fatemi, 2019). Nanomaterials played a paramount role in the protection and the delivery of genetic material biomolecules (growth differentiation factors) and in the determination and the regulation of stem cell behavior through tracing the fate and distribution of stem cells *in vivo*, ascertaining the origin of stem cell diseases, inducing directed differentiation of stem cells and regulating the microenvironment of tissues around stem cells (Arora *et al.*, 2012; Y. Sun *et al.*, 2020). These nanocarriers can be made of polymeric, lipid or inorganic materials (**Figure 1**) (Nemeth, Fine and Fatemi, 2019). In this section, we will review the common types of nanomaterials used in tissue engineering therapies and regenerative medicine.



**Figure 1:** Example of nanomaterials used in tissue engineering.

### 3.2.1 Polymeric based-nanomaterials

For polymeric based-nanoparticles (NPs), properties like size, shape, surface charge, mechanical strength, porosity, degradation rate and solubility, can be adjusted. In addition, these nanomaterials are known for their low cytotoxicity, good biocompatibility, improved targeting specificity and high permeation and retention effect (Fathi-achachelouei, Knopf-marques and Evelise, 2019). All these factors make polymeric based-NPs good tools for versatile purposes in tissue engineering and regenerative medicine. Various types of polymer based-NPs exist using biocompatible natural or synthetic polymers. Proteins (gelatin, elastin, albumin, silk), polysaccharides (alginate, dextran, chitosan, heparin, hyaluronic acid,), and synthetic polymers like polyesters, polyanhydrides, polyamides, polyacrylates and polyurethanes have been used single form or in conjugation with specific functional moieties or materials to provide functionalities in tissue engineering field. The macroscopic behavior of NPs is related to their morphology. Thus, depending on the application, choosing suitable type of NPs is a critical point in research (Fathi-

achachelouei, Knopf-marques and Evelise, 2019). Several techniques have been designed for the synthesis of NPs such as self-assembly, nanoprecipitation, single and double emulsion/solvent evaporation, emulsion polymerization, supercritical fluid, salting-out, emulsion/solvent diffusion, dialysis and microfluidic systems (Froioa *et al.*, 2020). Various types of polymer based-NPs exist:

### **A. Polymeric nanoparticle**

Polymeric nanoparticles are spherical polymeric colloidal particles with a size ranging from 10 to 1000 nm. They can be present as nanospheres or nanocapsules depending on the preparation method. The formers comprise a polymeric matrix extended from the core to the surface, while the latter consist on a polymeric layer surrounding a hollow core (Lammari *et al.*, 2020).

### **B. Dendrimer**

Dendrimers are highly branched, globular polymeric materials with nanometer-scale size much smaller than many organic counterparts. They are composed of a central core, an interior dendritic structure (the branches), and an exterior surface with functional surface groups like additional polymers or ligands enabling improved payload and targeting delivery (Gillies and Fréchet, 2005). Dendrimers, due to their structure, enable precise control of size and shape. The high surface area, neutral surface charge and water solubility, make polymeric dendrimers promising candidates for incorporation into tissue engineering scaffolds either as auxiliaries to an existing scaffold, or as primary scaffold components (Joshi and Grinstaff, 2008).

### **C. Micelle**

Polymeric micelles Polymeric micelles are nanosized molecules of core-shell structure that are formed by the self-assembly of amphiphilic block copolymers in an aqueous media (ML Adams, Lavasanifar and Kwon, 2003). Depending on the self-assembly principle, two forms of polymeric micelles exist: (i) block polymer micelles, which have a unique core-shell structure, with hydrophobic core and surrounding hydrophilic shells in aqueous solutions, and (ii) graft copolymer micelles, where different monomers are applied as main and branch chains enabling two or more opposite properties like oil/water affinity, plasticity/elasticity, and acidity/alkalinity (Bai *et al.*, 2020).

## **3.2.2 Inorganic based-nanomaterials**

Inorganic nanoparticles are also used for tissue engineering applications due to their benefits over organic nanoparticles including low toxicity, good storage stability, no microbial attack and easy preparation. However, they show only moderate transfection efficiencies (Sokolova and Epple, 2008). Many classes of inorganic-NPs have been used as carriers:

### **A. Metallic nanoparticle**

Metallic nanoparticles have a metal core made up of inorganic metal or metal oxide, generally covered with a shell composed of organic or inorganic material or metal oxide (AhmadKhan, 2020). Several methods are used to synthesize metallic-NPs like sol-gel process, spray pyrolysis, electrodeposition, rapid solidification, chemical vapour deposition, etc. Ag and Au are mainly used metal-NPs associated with many synthetic and natural polymers like chitosan, polyvinyl alcohol, polycaprolactone, etc. Several other metallic-NPs like Fe, Al, Cu, Ni, Zr and also magnetic nanoparticles are also applied (Wijesinghe *et al.*, 2020). Although some studies reported that some metal-NPs like nickel are toxic, it has been found that with the proper size and dosage, these NPs are mostly advantageous. Metallic-NPs find immense applications in tissue engineering and regenerative medicine areas due to their particular features including high surface area, antibacterial effect, electrical conductivity and biocompatibility (Eivazzadeh-keihan, Noruzi and Chenab, 2020). Metallic-NPs have also their advantage in therapy as drug carriers or as bioimaging agents (Ardoiwala, Kaundal and Choudhury, 2018). Furthermore, earlier studies reported that the ease of functionalization of metallic-NPs could enhance their biomedical applications and improve their performance in tissue engineering (Eivazzadeh-keihan, Noruzi and Chenab, 2020).

## **B. Ceramic nanoparticle**

Ceramic nanoparticle or nanoceramics are primarily composed of oxides, carbides, carbonates and phosphates of metals and metalloids like calcium, titanium, silicon, etc. They are classified as heat-resistant, inorganic and nonmetallic solids (Thomas, Harshita and Talegaonkar, 2015). They can be biodegradable (e.g. calcium phosphate and silica) or non-biodegradable (e.g. iron oxide, aluminum oxide). They are porous, less than 50 nm in size and can be found in various forms like polycrystalline, amorphous, porous, dense, or hollow (Sigmund *et al.*, 2006; Chen, Chen and Shi, 2013). Additionally, since they are not affected by pH fluctuations and temperature, they are suitable for protecting different biomacromolecules like enzymes against denaturation. Furthermore, due to their porous structure, they have a large surface area for incorporating bioactive molecules, and simultaneously they can be functionalized to include connective ligands. However, like the metallic-NPs, they are not biodegradable, which may cause side effects. Ceramic-NPs have a wide range of applications across the world. In the biomedical field, they are considered to be excellent carriers for drugs, proteins, genes, imaging agents etc. (Thomas, Harshita and Talegaonkar, 2015).

## **C. Quantum dots**

Quantum dots (QDs) are inorganic semiconductor nanocrystals that have a core/shell structure of 1-10 nm in diameter. They can be covered with amphiphilic polymers and conjugated with different ligands for targeted imaging approach (Bentolila, Ebenstein and Weiss, 2009). Cadmium selenide and cadmium telluride are some examples of QDs widely used for *in vivo* fluorescence imaging (Liu *et al.*, 2011). QDs are one of the most promising inorganic materials for stem cell research due to the fact that they can be synthesized easily in large quantities from various materials using moderately simple techniques. Moreover, they are good candidates for cell labeling, cell tracking and *in vivo* imaging, owing to their potential in imaging

and detection applications. For instance, QDs are robust fluorescent nanocrystals with narrow emission (Kim, 2008).

### **3.2.3 Lipid based-nanomaterials**

Lipid nanoparticles are particularly promising non-viral vectors used for tissue engineering and regenerative medicine applications especially for *in vivo* RNA delivery. Indeed, they can be synthesized easily in a scalable manner, facilitate endosomal escape, functionalized with specific ligands to target the desired or codelivered with adjuvants. In addition, most lipid NPs formulations rely on cationic lipids that efficiently complex the negatively charged RNA (Reichmuth *et al.*, 2016). In this review, we spotlight two types of lipid-NPs: liposomes and solid lipid nanoparticles.

#### **A. Liposome**

Liposomes generally consist of an aqueous core surrounded by a lipid bilayer shell. They were first described by Bangham *et al.* in the 1960s and were the first drug carriers used for targeted drug delivery (1965). The liposome bilayer consists of natural and/or synthetic phospholipids such as phosphatidylserine, phosphatidylcholine, phosphatidylinositol, phosphatidylglycerol and phosphatidylethanolamine (Laouini *et al.*, 2012). The phospholipid composition of the bilayer determines the properties of the liposome, such as surface charge, permeability, and hydrodynamics. Cholesterol may also be incorporated to improve the membrane fluidity and stability (Laouini *et al.*, 2012). Currently, liposomes have been approved for multiple clinical trials, and some liposome formulation products are already on the market (Malam, Loizidou and Seifalian, 2009; Yang *et al.*, 2011). The interest of liposomes is related to their ability to encapsulate both hydrophilic and hydrophobic drugs thanks to the amphiphilic structure of their consisting lipids. Furthermore, their small nano-size, biodegradability, biocompatibility, multi-route options for injection and their good cell affinity make them attractive carriers (Yang *et al.*, 2011).

#### **B. Solid lipid nanoparticles**

Despite the clinical success, the major limitations of liposomes as drug carriers are instability in bloodstream and uncontrolled and premature drug release (Yang *et al.*, 2011). Alternatively, solid lipid nanoparticles can instead be used for improved stability [23]. They are composed of surfactants and a lipid matrix that is solid at ambient temperature (Bayón-Cordero, Alkorta and Arana, 2019). The commonly used lipids are fatty acids (palmitic acid, stearic acid and benzoic acid), triacylglycerols (tristearin, trimyristin and tripalmitin) and acyl glycerols (glycerol monostearate, glycerol benzoate and glycerol palmitostearate) (Kaliyamurthi and Selvaraj, 2016). These lipids are characterized by their purity, good tolerability, low toxicity index, low price and biodegradability (Lin *et al.*, 2017). However, solid lipid nanoparticles show some limitations like reduced loading capacity of hydrophilic drugs (Mukherjee, Ray and Thakur, 2009). A second generation of lipid based NPs was developed in the aim of improving the loading capacity of solid lipid NPs; so called nanostructured lipid carriers in which the matrix is composed of a blend of a solid and a liquid lipid oil (Patel, 2013).

### 3.3 Scaffolds

A scaffold is a structural support engineered to mimic the function of a natural extracellular matrix contributing to the development of functional tissues for medical purposes (Monteiro *et al.*, 2015). Tissue engineering scaffolds can be made of natural or synthetic polymers. Natural polymers hold particular advantages over synthetic ones like commercial availability, superior biocompatibility, easy processing and the possibility to tune their degradation by changing the concentration of the polymer and/ or the cross-linking material (Garg *et al.*, 2011; Monteiro *et al.*, 2015). Natural polymers include collagens, albumin, dextran, starch, fibrin, alginate, gelatin, galactan, elastin, curdlan, chitosan, hyaluronic acid, cellulose, etc. Some limitations are attended when using these biomaterials like the price, the batch-to-batch variation and the cross-contamination (Garg *et al.*, 2011). Synthetic based-scaffolds are classified into two main groups: biodegradable polymers like polylactide, polyglycolide, polycaprolactone, polyurethane, polycyanoacrylate, etc. and non-biodegradable polymers like polyvinyl alcohol, poly (N-isopropylacrylamide) and polyhydroxyethylmethacrylate. Synthetic polymers have been suggested due to their processing flexibility and their ability to be manufactured in many sizes and shapes (Dawson *et al.*, 2008; Kulkarni *et al.*, 2010). The preparation methods of polymeric scaffold have been widely reviewed previously (Engel *et al.*, 2007). In addition to polymeric compounds, certain inorganic materials have also been used as scaffolds for tissue engineering applications. They are categorized into three main groups: bioactive, bioresorbable and bioinert depending on their ability to bond directly with native tissues once implanted. Bioactive materials (e.g., glass-ceramics and bioglasses) exhibit direct bonds with living tissues, and have been applied to fill small tissue defects and irregularities. On the other hand, bioresorbable materials (e.g., calcium phosphate, calcium phosphate cements, and calcium silicates or calcium carbonates) are gradually absorbed *in vivo* and are replaced by new tissues over time. Bioinert materials (e.g., titanium, zirconia, alumina and its alloys) applied as structural-support implants and have no interaction with their adjacent tissue after implantation (Pina *et al.*, 2019). The inorganic materials are frequently difficult to process into highly porous structures and are mechanically brittle. To solve these problems, combinations with natural or synthetic polymers have been proposed for tissue engineering research (Xie *et al.*, 2010; Haaparanta *et al.*, 2015). **Table 3.1** displayed some example of scaffold materials used for tissue engineering.

Material	Application	Reference
<b>Natural polymers</b>		
Hyaluronic acid	Brain regeneration	(Wang and Spector, 2009)
Collagen	Skin tissue regeneration	(Ahn <i>et al.</i> , 2010)
Salmon fibrinogen and chitosan	Wound healing	(Laidmae <i>et al.</i> , 2018)
<b>Synthetic polymers</b>		
Poly (lactide-co-glycolide)	Bone regeneration	(Go <i>et al.</i> , 2020)
Poly-L-lactic acid	Neural tissue engineering	(Yang <i>et al.</i> , 2005)
Polycaprolactone	Cartilage tissue engineering	(Li <i>et al.</i> , 2005)
Polyglycolic acid	Urinary tissue engineering	(Knight and Payne, 2013)
<b>Inorganic materials</b>		
Calcium silicate	Bone regeneration	(Shuai <i>et al.</i> , 2014)


Calcium phosphate	Cartilage tissue engineering	(H. Sun <i>et al.</i> , 2020)
Glass ceramic	-	(Mortera <i>et al.</i> , 2008)
<b>Hybrid materials</b>		
Poly (lactide-co-glycolide) + glass fibre	Bone regeneration	(Haaparanta <i>et al.</i> , 2015)
poly(l-lactide-co-glycolide) + tricalcium phosphate	Bone regeneration	(Xie <i>et al.</i> , 2010)
Polycaprolactone + chitosan	Skin tissue regeneration	(Levengood <i>et al.</i> , 2017)
Polyglycolic acid + collagen	Bone regeneration	(Levengood <i>et al.</i> , 2017)

**Table 1-** Example of scaffold materials for tissue engineering applications.

### 3.4 Applications of nanomaterials in tissue engineering and regenerative medicine

A scaffold can be used as a cell support device upon which cells are implanted into an artificial structure to support three dimensional tissue formation or as a drug delivery device by which drug release is sustained for longer period (Garg *et al.*, 2011). The combination of biomaterial scaffolds with bioactive agent-loaded nanomaterials has opened up a new avenue for tissue regeneration and has proven its efficiency in overcoming the limitations of traditional scaffold systems (Wang *et al.*, 2016). For instance, a traditional scaffold, when applied alone, shows limited ability to fully differentiate transplanted stem cells (Kulkarni *et al.*, 2010). In addition, the incorporation of bioactive agents directly into the scaffold induces poor bioavailability, high enzymatic degradation and possible self-aggregation (Lee *et al.*, 2008). The benefits of combining scaffolds with bioactive agent-loaded nanomaterials are: (i) the reduction of side effects, (ii) the protection of the bioactive agent from the degradation (iii) multiple bioactive agent delivery and (iv) the possibility of a sustained release (Santo, Gomes, *et al.*, 2012; Monteiro *et al.*, 2015). **Figure 2** demonstrated the combination of nanomaterials with scaffold systems. The nanomaterials can be confined within the scaffold and become free upon degradation of the scaffold by the cell (Yamauchi, Kato and Iwata, 2005). In another concept, nanomaterials can be immobilized onto the surface of scaffold. There are two ways of immobilization: (i) non-specific immobilization, which means that the nanosystems are adsorbed at the scaffold and are easily released during the cell culture at each medium exchange; (ii) specific immobilization where the nanomaterials are covalently bound at the surface of the scaffold, improving their stability (Nelson Monteiro *et al.*, 2014). The strategies used for nanomaterials-scaffolds combination have been already reviewed elsewhere (Rampichova, 2012; Wang *et al.*, 2012; N Monteiro, Martins, *et al.*, 2014; N Monteiro, Ribeiro, *et al.*, 2014)(Engel *et al.*, 2007). The bioactive agent delivered can be of two types: (i) growth/differentiation factor, by the introduction of the appropriate bioactive agent-loaded nanomaterials into the scaffold; and (ii) nucleic acid delivery, by cell delivery or by the introduction of the DNA (or RNAi) into a specific nanomaterial that silences (or encodes) a specific protein (Nelson Monteiro *et al.*, 2014). **Table 3.2** demonstrates the applications of

several types of nanomaterials combined with scaffolds for tissue engineering approaches.



**Figure 2:** Combination of nanomaterials with scaffold systems.

Nanocarrier	Scaffold	Bioactive agent	Application	Reference
<b>Liposomes</b>	scaffold	TGF- $\beta$ 1	Cartilage regeneration	(P Giannoni and Hunziker, 2003)
	PCL-scaffold	Dex	Bone regeneration	(N Monteiro, Martins, <i>et al.</i> , 2014)
	PCL-scaffold	Runx2-plasmid	Bone regeneration	(N Monteiro, Ribeiro, <i>et al.</i> , 2014)
<b>Polymeric nanoparticles</b>	Nanofibrous scaffold	TGF- $\beta$ , bFGF, IGF-I	Cartilage regeneration	(Mickova <i>et al.</i> , 2012)
	Collagen/chitosan scaffolds	TGF- $\beta$ 1 plasmid	Cartilage regeneration	(Cao <i>et al.</i> , 2012)
	Collagen sponge scaffold	BMP-2	Bone regeneration	(Zhang <i>et al.</i> , 2010)
	Chitosan Scaffolds with hyaluronic acid	TGF- $\beta$ 1 plasmid	Cartilage regeneration	(Lu <i>et al.</i> , 2013)
	PLGA scaffold	Anterior cruciate ligament	Ligament replacement	(Cooper, 2005)
	PCL scaffold	siRNA	Bone regeneration	(Andersen <i>et al.</i> , 2010)
	PEG and PCL	Rabbit	Chondrogenic	(Park, 2007)

	scaffold	chondrocytes	differentiation	
<b>Dendrimer</b>	Polyurethane sponge HA scaffolds	Dex	Bone regeneration	(Oliveira <i>et al.</i> , 2010)
<b>Micelles</b>	Gelatin scaffold	Triptolide and BMP-2	Bone regeneration	(Ratanavaraporn, Juruya and Tabata, 2012)
	Gelatin hydrogel with lactic acid oligomer	Dex	Bone regeneration	(Santo, Sato, <i>et al.</i> , 2012)
<b>Inorganic nanoparticles</b>	Magnetic NPs containing liposomes	hMSCs	Ischemic diseases	(Ishii <i>et al.</i> , 2011)
	Gold NPs	MSCs	Vascular regeneration	(Chen <i>et al.</i> , 2018)
	Cerium oxide NPs	HUVECs	Angiogenesis treatment	(Das <i>et al.</i> , 2012)
	ZnO NPs	HUVECs	Angiogenesis treatment	(Augustine <i>et al.</i> , 2014)


**Table 2-** Examples of nanomaterials combined with scaffolds for tissue engineering approaches.

TGF- $\beta$ 1 transform growth factor  $\beta$ ; PCL-polycaprolactone; Dex-dexamethasone; Runx2- runt-related transcription factor 2; FGF-fibroblast growth factor; IGF-I-insulin-like growth factor I; BMP-bone morphogenetic protein; PLGA – poly (lactic acid-co-glycolic acid); siRNA e small interfering RNA; PEG – poly (ethylene glycol); NPs- nanoparticles; hMSCs- human mesenchymal stem cells; MSC- mesenchymal stem cells; HUVECs - human umbilical vein endothelial cells; ZnO-zinc oxide.

### 3.4.1 Growth/differentiation factors delivery

Cell activities such as differentiation, proliferation, migration, and protein expression are mediated by growth factors. Growth factors are endogenous polypeptides, normally produced by healthy cells and act through the cell-surface receptors regulating cellular activities which in turn lead to tissue regeneration (Quaglia, 2008). In certain cases, where tissue regeneration does not occur naturally, growth factors need to be delivered exogenously (**Figure 3.a**) (Vasita and Katti, 2014). Numerous studies have demonstrated the use of nanomaterial-scaffold systems as carriers for the controlled delivery of growth factors improving stem cell proliferation and differentiation *in vitro* (**Table 3.3**). Rampichova *et al.* noticed that the conjugation of fetal bovine serum loaded liposomes with poly (2-hydroxyethyl methacrylate) scaffold enhanced the adhesion and the proliferation of chondrocyte (Rampichova, 2012). The *in vitro* and *in vivo* studies carried by Park *et al.* revealed that transplanted human mesenchymal stem cells encapsulated in a fibrin hydrogel containing heparinized nanoparticles loaded with TGF- $\beta$ 3 constitute a clinically efficient tool for the regeneration of hyaline articular cartilage (Park *et al.*, 2011). Furthermore, it was found that PLGA scaffolds containing IGF-I and TGF- $\beta$ 1 loaded PNIPAM nanoparticles provided more expression of collagen type II and aggrecan than those containing free or single growth factors (Ertan *et al.*, 2013). Several studies revealed that the encapsulation of growth factors in nanomaterials provides slow delivery in tissue engineering approaches (Paolo Giannoni and Hunziker, 2003; Jung *et al.*, 2009). Jung *et al.* noticed that the *in situ* chondrogenic differentiation of the hASCs was induced and sustained by the continuous release of TGF- $\beta$ 1 from

pluronic heparin NPs seeded onto PCL scaffolds (Jung *et al.*, 2009). Similarly, Giannoni *et al.* stated that the conjugation of TGF- $\beta$ 1-loaded liposomes with scaffolds represents a suitable means of establishing a slow release over a period of some weeks, enhancing its release kinetics and local efficacy and avoiding the typical side effects upon systemic administration. For instance, they found that only 40% of TGF- $\beta$ 1 had been released from fibrin clots containing liposome, as compared with those containing the free molecules, where 68% were released after 25 days (Paolo Giannoni and Hunziker, 2003).



**Figure 3:** Application of nanomaterial-scaffolds system in tissue engineering and regenerative medicine (Example of myocardial infarctions).

Growth factor	Material	Comments	Application	Reference
TGF- $\beta$ 1	Liposome-scaffold	Less side effects upon systemic administration	Cartilage regeneration	(P Giannoni and Hunziker, 2003)
FBS	Poly(2-hydroxyethyl methacrylate) fibrous scaffold - liposomes	Enhanced chondrocyte adhesion and proliferation	-	(Rampichova, 2012)
TGF- $\beta$ 1	PLCL scaffold - PLGA/Pluronic heparin NPs	Differentiation of hASCs to chondrogenic lineage was induced and sustained.	Cartilage regeneration	(Jung <i>et al.</i> , 2009)
IGF-I + TGF1	PLGA scaffolds - PLGA and PNIPAM NPs	Improved expression of collagen type II and aggrecan	Cartilage regeneration	(Ertan <i>et al.</i> , 2013)
TGF- $\beta$ 3	Fibrin hydrogel - heparin NPs	hMSCs embedded in fhydrogels proliferated more readily in samples containing TGF- $\beta$ 3-loaded nanoparticles compared to those containing the fibrin hydrogel alone.	Cartilage regeneration	(Park <i>et al.</i> , 2011)
BMP-2	Fibrin hydrogels with heparin - PLGA NPs	Obtention of more mature and highly-mineralized bone	Bone regeneration	(Chung <i>et al.</i> , 2007)
BMP-2	Fibrin hydrogel - heparin NPs	More potent effects of hMSCs on bone regeneration for fibrin containing encapsulated form than those with un-encapsulated form.	Bone regeneration	(Park <i>et al.</i> , 2009)
BMP-2 + BMP-7	Chitosan-PEO scaffolds - PLGA and PHBV NPs	Synergistic effect of using two growth factors on alkaline phosphatase expression.	Bone regeneration	(Yilgor <i>et al.</i> , 2009)
BMP-2	Collagen sponge scaffold - PEI coated albumin NPs	reduced initial burst release and prolonged retention at implantation site.	Bone regeneration	(Zhang, Doschak and Uludag, 2009)

TGF-b1-transform growth factor b1; FBS-fetal bovine serum; PLCL-poly(lactide-co-caprolactone); PLGA-poly(lactic acid-co-glycolic acid); NPs-nanoparticles; HASCs- human adipose tissue-derived stem cells; IGF-I-insulin-like growth factor I; PNIPAM - poly(N-isopropylacrylamide); hMSCs-human mesenchymal stem cells; BMP- bone morphogenetic protein-2; PEO-poly(ethyleneoxide); PHBV-poly(3-hydroxybutyrateco-3-hydroxyvalerate); PEI- polyethylenimine.

**Table 3.** Examples of nanomaterials-based strategies for growth factors release in tissue engineering and regenerative medicine approaches.

### 3.4.2 Therapeutic gene delivery

The use of growth/differentiation factors is challenging as they have short half-lives and may denature during the encapsulation processes. Furthermore, the long time periods that cells took to reach the differentiated state, the use of combinations of growth factors and the difficulty to differentiate the cells into one specific lineage are considered as other factors that limit the use of growth/differentiation factors in tissue engineering approaches (Yau *et al.*, 2012). Engineering tissues through gene therapy to synthesize and secrete proteins like growth factors represents an alternative approach to overcome these limitations and to control stem cell differentiation (Galli *et al.*, 2021). Gene therapy can be used for gene augmentation, gene editing, or gene silencing depending on the final goal (Itziar, Rodr and Vicente-pascual, 2020). Gene therapy consists on the insertion of the vector containing the functioning gene (nucleic acid) into the host cell to replace a hereditary genetic defect or, to provide a new function such as overexpressing growth factors or even killing undesirable cells (like cancer cells) (**Figure 3.b**) (Nelson Monteiro *et al.*, 2014). Diverse nucleic acids are being used for this purpose. DNA and messenger RNA (mRNA) provide protein expression, whereas, microRNA, small interfering RNA (siRNA), aptamers or oligonucleotides induce gene silencing (Pozo-Rodríguez *et al.*, 2019). The *ex vivo* technique, generally carried out for the delivery of genes, uses autologous cells that are recovered from the patient's body. The cells are generally transduced with viral or non-viral vectors and re-inserted into the target tissue (Winn *et al.*, 2005). Viral vectors (i.e. lentivirus and retrovirus) are known for their high transfection efficiency and transgene expression. Non-viral vectors (i.e. polymers, liposomes, cationic lipids and proteins) have comparatively lower transduction efficiency, but they have been widely proposed due to their easy production, safety, tissue selectivity, effective delivery, higher pDNA size encapsulation and flexibility in formulation. Nanomaterials–scaffold systems may be effective in tissue engineering applications by delivering genes in a cell-controlled, efficient, and spatially localized manner. The combination may obviate the issues of toxicity, silencing efficiency and long-term expression (Nelson Monteiro *et al.*, 2014). Numerous studies have been conducted to apply these systems for gene delivery improving stem cell proliferation and differentiation *in vitro* (**Table 3.4**). Guo *et al.* found that the repair of cartilage defects in rabbits' knees was enhanced by TGF- $\beta$ 1 gene-modified-tissue engineering of cartilage on the basis of a strategy using autologous MSCs, chitosan scaffold and liposomal transfection (Guo *et al.*, 2007). Furthermore, Kulkarni *et al.* revealed that fibrin microspheres can be utilized for gene delivery to extend the capacity of a fibrin scaffold to preserve the structural integrity and functional integrity of DNA (Kulkarni *et al.*, 2011). In another study, it was observed that BMP-4- transfected ASCs seeded onto PLLGA scaffold significantly improved *in vivo* chondrogenesis in a rabbit articular defect model (Shi *et al.*, 2013). Moreover, the transfection efficiencies of the liposome and PEI complexes were enhanced *in vitro* when released from resorbable gene-activated matrix (Bolliet, Bohn and Spector, 2008). Liu *et al.* investigated carbon nanotube delivery of siRNA against CXCR4, a cell-surface receptor necessary for HIV entry into human T cells and found that 90 % silencing efficiency was observed upon incubation for 3 days (Liu *et al.*, 2007).

Gene	Material	Comments	Application	Reference
pDNA-NGF	fibronectin-coated PLG	Polymer-mediated transfection of HEK293T with an NGF-encoding plasmid resulted in outgrowth by dorsal root ganglia neurons.	Neural regeneration	(Whittlesey and Sheaa, 2006)
pDNA-bGal-EGFP	fibrin scaffold	the fibrin-lipoplex system produced higher transfection efficiency for two reporter genes at day 7.	Multiple gene delivery	(Kulkarni <i>et al.</i> , 2009)
pDNA	fibrin scaffold–fibrin microsphere	fibrin microspheres can extend the capacity of fibrin scaffolds and were able to degrade and release DNA differentially.	Gene delivery	(Kulkarni <i>et al.</i> , 2011)
pDNA-encoding BMP4	GAM-liposomes	GAM technology enhances the release duration and functional stability of incorporated DNA.	Bone regeneration	(Bolliet, Bohn and Spector, 2008)
pDNA-TGF-b1	chitosan scaffolds-liposome	defect filled with regenerated hyaline-like cartilage tissue twelve weeks after implantation.	Cartilage regeneration	(Guo <i>et al.</i> , 2007)
BMP4 plasmid	PLLGA scaffold- PLGA NPs	improved <i>in vivo</i> chondrogenesis in a rabbit articular defect model.	Cartilage regeneration	(Shi <i>et al.</i> , 2013)
si-RNA	PCL scaffold-PCL NPs	gene silencing of TRIB <sub>2</sub> and BCL <sub>2</sub> L <sub>2</sub> in enhancing adipogenic osteogenic and differentiation, respectively.	Bone regeneration	(Andersen <i>et al.</i> , 2010)
siRNA	PEG-PAMA-Gold NPs	significant RNAi activity in HuH-7 cells.	Gene delivery	(Motoi <i>et al.</i> , 2006)
siRNA	Carbon nanotubes	90 % silencing efficiency was observed upon incubation for 3 days.	HIV treatment	(Liu <i>et al.</i> , 2007)
HER <sub>2</sub> siRNA	Quantum-dot based chitosan NPs	gene silencing was occurred after functionalization of the particle surface with HER <sub>2</sub> that target specific receptors on the cell surface	Gene delivery	(Tan, Jiang and Zhang, 2007)
DNA	Silica NPs	the uptake of DNA into cells was shown by adsorbing on the cell surface.	DNA vaccination	(Luo <i>et al.</i> , 2004)

pDNA-Luc-EGFP	PLGA-Polyplexes	enhanced reporter gene expression up to 1500-fold, compared to unmodified substrates.	gene delivery	(Bengali <i>et al.</i> , 2009)
pDNA-bGal, pDNA-Luc-EGFP	lipoplex	the presence of the peptide in the lipoplex increased internalization efficiency by up to 4.5-fold.	gene delivery	(Rea <i>et al.</i> , 2009)
pDNA-BMP2-VEGF-BMP-2-VEGF	liposome	high levels of BMP-2 and hVEG are secreted.	bone regeneration	(Guo-ping <i>et al.</i> , 2010)

GAM- gene-activated matrix; NGF- nerve growth factor; PLG- poly(lactide-co-glycolide); TGF- transforming growth factor; EGFP- enhanced green fluorescent protein; bGal- encoding b-galactosidase; MSCs- mesenchymal stem cells; PLLGA - poly(Llactic-co-glycolic acid); HA- hydroxylapatite; PEG-PAMA, poly(ethylene glycol)-block-poly(2-(N,N-dimethylamino)ethyl methacrylate) copolymer; PLGA- poly(lactide-co-glycolide); Luc-luciferase; BMSCs-Bone marrow mesenchymal stem cells; BMPs- Bone morphogenetic proteins; VEGF- vascular endothelial growth factor; hBMP-2- human bone morphogenetic protein 2; hVEGF165- vascular endothelial growth factor 165.

**Table 4.** Examples of nanomaterials-based strategies for gene delivery in tissue engineering and regenerative medicine approaches.

### 3.4.3 Cell delivery

Cell therapy consists on introducing new cells into a tissue in the aim of treating a specific disease. Cell-based tissue engineering is one of the most widely used tissue engineering methodologies in the literature and is linked with particular benefits. These include the direct placement of cells into a defected tissue, which decreases considerably the expected lag phase for progenitor cell recruitment to the defect site (Galli *et al.*, 2021). The most widely used stem cells include periodontal ligament cells, bone marrow stromal cells, endothelial progenitor cells, dental pulp stem cells, mesenchymal stem cells, etc (Hare *et al.*, 2009; Peters, 2018; Galli *et al.*, 2021).

Nanomaterials play a paramount role in regulating stem cell behavior because of their special characteristics, including size, shape, surface charge, and surface area. Many studies have been reported in the literature investigating the role of nanomaterials in stem cells based-therapy, as illustrated in **Table 3.5**. The advantage of applying nanomaterials include tracking the stem cells *in vivo* for long-term (**Figure 3.c**) (Y. Sun *et al.*, 2020). SPIONs mark stem cells by three main ways: (i) attaching NPs to the cell surface, (ii) receptor-mediated endocytosis, and (iii) transfecting agent-mediated endocytosis (Frank *et al.*, 2002). The first approach is always limited due to the fact that the reticuloendothelial system recognizes and clears SPION-labeled cells. However, they can persist in the cytoplasm of stem cells where they are biocompatible through the internalization pathway (Y. Sun *et al.*, 2020). QDs are widely used in long-term monitoring in living cells, as compared to traditional fluorescent probes (Liu *et al.*, 2019). Numerous studies have investigated the possibility of labeling stem cells through several modifications like electroporation (Sun *et al.*, 2014), bioconjugation (Shah and Mao, 2011) and delivery by phospholipid micelles (Dubertret *et al.*, 2002), all of which preserve the safety and stability of the label. Silica dioxide NPs are used as ultrasound contrast agents, widely associated with radionuclides, fluorescein or helium ions to enhance the imaging of the stem cells, hence facilitating stem cell tracking (Accomasso *et al.*, 2012).

Another advantage of applying nanomaterials in cell based therapy is the improvement of the stem cells retention after their transplantation (**Figure 3.d**). Stem cells can be administrated via several routes (Y. Sun *et al.*, 2020). The application of stem cell therapy is generally limited by the low cell retention after transplantation. It has been reported that NPs can increase stem cell retention by creating a cardiac-specific extracellular matrix environment, promoting the interactions with cardiomyocytes and affecting the focal adhesion complex of myocardial MSCs (Popara *et al.*, 2018). In another study, it has been noticed that applying SPION-labeled MSCs with a magnetic field might improve cell homing of MSCs at the site of injury and result in enhancing the cardiac function and attenuating the injury after heart failure (Naseroleslami, Aboutaleb and Parivar, 2018).

<b>Application of nanomaterials in stem cells tracking</b>						
<b>Stem cells</b>	<b>Nanomaterial</b>	<b>Imaging modality</b>	<b>Model</b>	<b>Application</b>	<b>Properties</b>	<b>Reference</b>
hMSCs	Au@BSA@PLL nanotracers	CT	Mouse	Lung repair	labeled MSCs were tracked for up to 23 d after transplantation by CT imaging.	(Ning <i>et al.</i> , 2019)
hMSCs	USPIO	MRI	IHD Patient	Heart disease	labeled MSCs could be tracked by semiautomated regional T2 relaxation time analysis 14 days after transplantation at injection sites.	(Mathiasen <i>et al.</i> , 2019)
hESC-CPCs	Iron oxide NPs	MRI	Pig	Heart disease	MRI is effective in tracking the location and dispersion of cell grafts.	(Skelton <i>et al.</i> , 2016)
oligodendrocyte progenitors	Magnetic NPs	MRI	Rat	Neuron repair	the iron particles remain localized and are not taken up by other cells even after 14 days.	(Bulte <i>et al.</i> , 1999)
hESC-CMs	PANPs	PAI	Rat	Heart disease	PANPs provide high efficiency for cells labeling without adverse effects on cell function, structure, and gene expression	(Qin <i>et al.</i> , 2018)
Neural stem cells	Au-MION	MRI	Rat	-	MRI signals correlated with gold-positive staining of transplanted cells.	(Wang, Lee and Holmström, 2006)
hMSCs	SiO <sub>2</sub> -NPs	Immunofluorescence	Rat	Heart disease	SiO <sub>2</sub> -NPs show high compatibility in terms of lack of cyto- and genotoxicity.	(Gallina <i>et al.</i> , 2015)
<b>Application of nanomaterials in improving stem cells retention after transplantation</b>						
<b>Stem cells</b>	<b>Nanomaterial</b>	<b>Model</b>	<b>Application</b>	<b>Properties</b>	<b>Reference</b>	
hMSCs	SiO <sub>2</sub> -NP	<i>In vitro</i>	Heart disease	increased <i>in vitro</i> adhesion capacity of hMSCs	(Popara <i>et al.</i> , 2018)	
MSCs	SPION	Rat	Heart disease	improve cell homing of MSCs at the site of injury and result in enhancing the cardiac function and attenuating the injury after heart failure	(Naseroleslami, Aboutaleb and Parivar, 2018)	

hMSCs- ; AuNP-Gold nanoparticles; BSA-bovine serum albumin; PLL- poly-L-lysine; CT-computer tomography; hESC-CPCs - embryonic stem cell-derived cardiac progenitors; USPIO-ultrasmall paramagnetic iron oxide; MRI-magnetic resonance imaging- IHD-ischemic heart disease; hESC-CMs - embryonic stem cell-derived cardiomyocytes ;PAI- photoacoustic imaging; PANPs-photoacoustic nanoparticles; Au-MION-monocrystalline iron oxide nanoparticles; hCPC-human cardiac progenitor cell; SPION- superparamagnetic iron oxide nanoparticles.

**Table 5.** Examples of nanomaterials-based strategies for cell therapy in tissue engineering and regenerative medicine approaches.

### 3.5 Conclusion

In this chapter, we spotlight the inimitable and advanced features of nanomaterials for rapid development of nanotechnology-based tissue engineering and regenerative medicine applications. Numerous studies have revealed the potential of nanomaterials–scaffold systems in that field through delivering growth/differentiation factors and genes in a cell-controlled, efficient, and spatially localized manner and regulating stem cell behavior by improving stem cells tracking and retention after transplantation. Several kinds of nanomaterials are used to protect, control the release of bioactive molecules, decrease the site effects and track the cells. They include polymeric, lipid and inorganic based materials. Each material has its own features; polymers can improve the efficiency, enhance the targeting specificity and reduce the cytotoxicity; lipids have been approved for multiple clinical trials; while, inorganic systems have good storage stability, no microbial attack and simple fabrication requirements. Therefore, the choice of the appropriate system is a crucial key to gain specific requests.

### 3.6 Reference

Accomasso, L. *et al.* (2012) Fluorescent silica nanoparticles improve optical imaging of stem cells allowing direct discrimination between live and earlystage apoptotic cells. *Smalls*, 8, 3192–3200.

AhmadKhan, S. In: Shah MR, editor. *Metal Nanoparticles for Drug Delivery and Diagnostic Applications*. Chapter 1 - Metal nanoparticles toxicity: role of physicochemical aspects. Elsevier: 2020. pp. 1–11.

Ahn, S. H. *et al.* (2010) Designed three-dimensional collagen scaffolds for skin tissue regeneration. *Tissue Engineering Part C Methods*, 16, 813–820.

Andersen, M. *et al.* (2010) siRNA nanoparticle functionalization of nanostructured scaffolds enables controlled multilineage differentiation of stem cells. *Mol Ther*, 18, 2018–2027.

Anthony, S. and Borlongan, C. V (2017) Recent progress in regenerative medicine for brain disorders. *Brain circulation*, 3,121–123.

Ardoiwala, M. N., Kaundal, B. and Choudhury, S. R. In: HussainCM, editor. *Handbook of Nanomaterials for Industrial Applications*. Chapter 37 - Development of Engineered Nanoparticles Expediting Diagnostic and Therapeutic Applications Across Blood–Brain Barrier. Elsevier: 2018. pp. 696–709.

Arora, P. *et al.* (2012) Nano-regenerative medicine towards clinical outcome of stem cell and tissue engineering in humans. *Journal of Cellular and Molecular Medicine*, 16(9),1991–2000.

Augustine, R. *et al.* (2014) Investigation of angiogenesis and its mechanism using zinc oxide nanoparticle-loaded electrospun tissue engineering scaffolds. *RSC Advances*, 4, 51528–51536.

Bai, S. *et al.* (2020) Polymeric micelles as delivery systems, in *Nanoengineered Biomaterials for Advanced Drug Delivery*. Elsevier Ltd., pp. 261–278.

Bangham, A. D., Standish, M. M. and Watkins, J. C. (1965) 'Diffusion of univalent ions across the lamellae of swollen phospholipids', *Journal of molecular biology*, 13(1), pp. 238–252.

Bayón-Cordero, L., Alkorta, I. and Arana, L. (2019) Application of solid lipid nanoparticles to improve the efficiency of anticancer drugs. *Nanomaterials*, 9(3), 474.

Bengali, Z. *et al.* (2009) Gene delivery through cell culture substrate adsorbed DNA complexes. *Biotechnol. Bioeng*, 90, 290–302.

Bentolila, L. A., Ebenstein, Y. and Weiss, S. (2009) Quantum dots for in vivo small-animal imaging. *Journal of Nuclear Medicine*, 50(4), 493–496.

Bolliet, C., Bohn, M. C. and Spector, M. (2008) Non-viral delivery of the gene for glial cell line-derived neurotrophic factor to mesenchymal stem cells in vitro Vva a collagen scaffold. *Tissue Engineering Part C Methods*, 14, 207–219.

Bulte, J. *et al.* (1999) Neurotransplantation of magnetically labeled oligodendrocyte progenitors: Magnetic resonance tracking of cell migration and myelination. *Proceedings of the National Academy of Sciences of the United States of America*, 96, 15256–15261.

Cao, X. *et al.* (2012) Incorporating ptgfbeta 1/calcium phosphate nanoparticles with fibronectin into 3-dimensional collagen/chitosan scaffolds: efficient, sustained gene delivery to stem cells for chondrogenic differentiation. *Eur Cell Mater*, 23, 81–93.

Chen, Y. *et al.* (2018) Functional engineered mesenchymal stem cells with fibronectin-gold composite coated catheters for vascular tissue regeneration. *Nanomedicine*, 14, 699–711.

Chen, Y., Chen, H. and Shi, J. (2013) In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles. *Advanced Materials*, 25, 3144–3176.

Chung, Y. *et al.* (2007) Enhanced bone regeneration with BMP-2 loaded functional nanoparticle-hydrogel complex. *Journal of Controlled Release*, 121, 91–99.

Cooper, J. (2005) Fiber based-tissue engineered scaffold for ligament replacement: design considerations and in vitro evaluation. *Biomaterials*, 26, 1523–1532.

Curtin, C. M., Castaño, I. M. and O'Brien, F. J. (2017) Scaffold-based microRNA therapies in regenerative medicine and cancer. *Advanced healthcare materials*, 7, 1700695.

Das, S. *et al.* (2012) The induction of angiogenesis by cerium oxide nanoparticles through the modulation of oxygen in intracellular environments. *Biomaterials*, 33,

7746–7755.

Dawson, E. *et al.* (2008) Biomaterials for stem cell differentiation. *Advanced Drug Delivery Reviews*, 60, e28.

Dubertret, B. *et al.* (2002) In vivo imaging of quantum dots encapsulated in phospholipid micelles. *Science*, 298, 1759–1762.

Dvir, T. *et al.* (2011) Nanotechnological strategies for engineering complex tissues. *Nat Nanotechnol*, 6, 13–22.

Eivazzadeh-keihan, R., Noruzi, E. B. and Chenab, K. K. (2020) 'Metal-based nanoparticles for bone tissue engineering. *Journal of tissue engineering and regenerative medicine*, 14, 1687–1714.

Engel, E. *et al.* (2007) Nanotechnology in regenerative medicine : the materials side. *Trends Biotechnology*, 26, 39–47..

Ertan, A. *et al.* (2013) Effect of double growth factor release on cartilage tissue engineering. *J Tissue Eng Regen Med*, 7, 149–160.

Fathi-achachelouei, M., Knopf-marques, H. and Evelise, C. (2019) Use of nanoparticles in tissue engineering and regenerative medicine. *Front. Bioeng. Biotechnol*, 7, 1–22.

Frank, J. *et al.* (2002) Magnetic intracellular labeling of mammalian cells by combining (FDA approved) superparamagnetic iron oxide MR contrast agents and commonly used transfection agents. *Academic radiology*, S484–S487.

Froio, F. *et al.* In: Nguyen TA, editor. Micro and Nano Technologies. Chapter 16 - Polymer-based nanocontainers for drug delivery. Elsevier Science Publishing Co Inc: 2020. pp. 271–285.

Galli, M. *et al.* (2021) Current and future trends in periodontal tissue engineering and bone regeneration. *Plastic and Aesthetic Research*, 8, 3.

Gallina, C. *et al.* (2015) Human mesenchymal stem cells labelled with dye-loaded amorphous silica nanoparticles: long-term biosafety, stemness preservation and traceability in the beating heart. *Journal of Nanobiotechnology*, 13, 77.

Gao, Y. *et al.* (2015) Emerging translational research on magnetic nanoparticles for regenerative medicine. *Chemical Society Reviews*. Royal Society of Chemistry, 44, 6306–6329.

Garg, T. *et al.* (2011) Scaffold: Tissue engineering and regenerative medicine. *International Research Journal of Pharmacy*, 2, 37–42.

Giannoni, P and Hunziker, E. (2003) Release kinetics of transforming growth factor-beta 1 from fibrin clots, *Biotechnol. Bioeng*, 83, pp. 121–123.

Gillies, E. and Fréchet, J. (2005) Dendrimers and dendritic polymers in drug delivery. *Drug discovery today*, 10, 35–43.

Go, E. J. *et al.* (2020) An osteoconductive PLGA scaffold with bioactive  $\beta$ -TCP and anti-inflammatory Mg(OH)<sub>2</sub> to improve in vivo bone regeneration. *Biomaterials science*, 8, 937–948.

Guo-ping, W. *et al.* (2010) Influence on the osteogenic activity of the human bone marrow mesenchymal stem cells transfected by liposome-mediated recombinant plasmid pIRES-hBMP2-hVEGF165 in vitro. *Annal of plastic surgery*, 65, 80–84.

Guo, C.-A. *et al.* (2007) Novel gene-modified-tissue engineering of cartilage using stable transforming growth factorbeta 1-transfected mesenchymal stem cells grown on chitosan scaffolds. *Journal of bioscience and bioengineering*, 103, 547–556.

Haaparanta, A.-M. *et al.* (2015) Improved dimensional stability with bioactive glass fibre skeleton in poly(lactide-co-glycolide) porous scaffolds for tissue engineering. *Materials Science & Engineering C*, 56, 457–466.

Hare, J. *et al.* (2009) A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. *J. Am. Coll. Cardiol*, 54, 2277–2286.

Ishii, M. *et al.* (2011) Enhanced angiogenesis by transplantation of mesenchymal stem cell sheet created by a novel magnetic tissue engineering method. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 31, 210–2215.

Itziar, G., Rodr, J. and Vicente-pascual, M. (2020) Nanomedicines to deliver mRNA : state of the art and future perspectives. *Nanomaterials*, 10, 364.

Joshi, N. and Grinstaff, M. (2008) Applications of dendrimers in tissue engineering applications of dendrimers in tissue engineering. *Current topics in medicinal chemistry*, 8, 1225–36.

Jung, Y. *et al.* (2009) In situ chondrogenic differentiation of human adipose tissue-derived stem cells in a TGF-beta(1) loaded fibrin-poly(lactide-caprolactone) nanoparticulate complex. *Biomaterials*, 30, 4657–4564.

Kaliyamurthi, S. and Selvaraj, G. (2016) Insight on solid lipid nanoparticles: characterization and application in diabetes mellitus. *Journal of critical reviews*, 3(4), 11–16.

Kim, J. D. (2008) Nanotechnology for regenerative medicine : nanomaterials for stem cell imaging. *Nanomedicine*, 3, 567–578.

Knight, T. A. and Payne, R. G. (2013) Characterization of a PGA-based scaffold for use in a tissue-engineered neo-urinary conduit. *Methods in molecular biology*, 1001, 179–188.

Kulkarni, M. *et al.* (2009) Fibrin-lipoplex system for controlled topical delivery of multiple genes. *Biomacromolecules*, 10,1650–1654.

Kulkarni, M. *et al.* (2010) Liposomal gene delivery mediated by tissue engineered scaffolds. *Trends Biotechnology*, 28, e36.

Kulkarni, M. M. *et al.* (2011) A temporal gene delivery system based on fibrin microspheres. *Mol. Pharmaceutics*, 8, 439–446.

Laidmae, I. *et al.* (2018) Salmon fibrinogen and chitosan scaffold for tissue engineering: in vitro and in vivo evaluation. *Journal of Materials Science: Materials in Medicine*, 29, 182.

Lammari, N. *et al.* In: Fitzpatrick D, editor. Drug Delivery Devices and Therapeutic Systems. Encapsulation methods of active molecules for drug delivery. Elsevier; 2020. pp 289-306.

Laouini, A. *et al.* (2012) 'Preparation , characterization and applications of Lliposomes : State of the art. *Journal of Colloid Science and Biotechnology*, 1(2), 147–168.

Lee, J. *et al.* (2008) Controlled dual release of basic fibroblast growth factor and indomethacin from heparin-conjugated polymeric micelle. *International journal of pharmaceutics*, 346, 57.

Lee, R. T. and Walsh, K. (2016) The future of cardiovascular regenerative medicine. *Circulation*, 133, 2618–2625.

Levengood, S. L. *et al.* (2017) Chitosan–poly(caprolactone) nanofibers for skin repair. *Journal of Materials chemistry B*, 5,1822–1833.

Li, W. W. J. *et al.* (2005) A three-dimensional nanofibrous scaffold for cartilage tissue engineering using human mesenchymal stem cells. *Biomaterials*, 26, 599–609.

Liao, S., Chan, C. and Ramakrishna, S. (2008) Stem cells and biomimetic materials strategies for tissue engineering. *Mater Sci Eng C Biomimetic Supramol Syst*, 28, 1189–1202.

Lin, C. *et al.* (2017) Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers. *J Food Drug Anal*, 25, 219–234.

Liu, X. *et al.* (2019) A brief review of cytotoxicity of nanoparticles on mesenchymal stem cells in regenerative medicine. *International journal of nanomedicine*, 14, 3875–3892.

Liu, Y. *et al.* (2011) Optical probes and the applications in multimodality imaging. *Contrast Media & Molecular Imaging*, 6(4), 169–177.

Liu, Z. *et al.* (2007) siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. *Angewandte Chemie*, 119, 2069–2073.

Lu, H. *et al.* (2013) 'Porous chitosan scaffolds with embedded hyaluronic acid/chitosan/plasmid-DNA nanoparticles encoding TGF-beta 1 induce DNA controlled release, transfected chondrocytes, and promoted cell proliferation', *PLoS One*, 8.

Luo, D. *et al.* (2004) A self-assembled, modular DNA delivery system mediated by silica nanoparticles. *Journal of Controlled Release*, 95, 333–341.

Malam, Y., Loizidou, M. and Seifalian, A. (2009) Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. *Trends in Pharmacological Sciences*, 30, 592–599.

Mathiasen, A. *et al.* (2019) In vivo MRI tracking of mesenchymal stromal cells labeled with ultrasmall paramagnetic iron oxide particles after intramyocardial transplantation in patients with chronic ischemic heart disease. *Stem Cells Int*, 2019, 2754927.

Mickova, A. *et al.* (2012) Core/ Shell nanofibers with embedded liposomes as a drug delivery system. *Biomacromolecules*, 13, 952–962.

ML Adams, Lavasanifar, A. and Kwon, G. (2003) Amphiphilic block copolymers for drug delivery. *Journal of Pharmaceutical Science*, 92, 1343–1355.

Monteiro, N, Martins, A., *et al.* (2014) Immobilization of bioactive factor-loaded liposomes at the surface of electrospun nanofibers targeting tissue engineering. *Biomater. Sci*, 2, 1195–1209.

Monteiro, N, Ribeiro, D., *et al.* (2014) Instructive nanofibrous scaffold comprising runt-related transcription factor 2 gene delivery for bone tissue engineering. *ACS Nano*, 8, 8082–8094.

Monteiro, Nelson *et al.* (2014) Liposomes in tissue engineering and regenerative medicine', *Journal of the royal society interface*, 11, 20140459.

Monteiro, N. *et al.* (2015) Nanoparticle-based bioactive agent release systems for bone and cartilage tissue engineering. *Regenerative Therapy*, 1, 109–118.

Mortera, R. *et al.* (2008) Synthesis and characterization of MCM-41 spheres inside bioactive glass–ceramic scaffold. *Chemical Engineering Journal*, 137, 54–61.

Mostafavi, E. *et al.* (2020) Electroconductive nanobiomaterials for tissue engineering and regenerative medicine', *Bioelectricity*, 2, 2.

Motoi, O. *et al.* (2006) Smart PEGylated Gold Nanoparticles for the Cytoplasmic

Delivery of siRNA to Induce Enhanced Gene Silencing. *Chemistry letters*, 35, 1046–1047.

Mukherjee, S., Ray, S. and Thakur, R. (2009) Solid lipid nanoparticles: a modern formulation approach in drug delivery system. *Indian J Pharm Sci*, 71, 349–358.

Naseroleslami, M., Aboutaleb, N. and Parivar, K. (2018) The effects of superparamagnetic iron oxide nanoparticles-labeled mesenchymal stem cells in the presence of a magnetic field on attenuation of injury after heart failure. *Drug Deliv. Transl. Res.*, 8, 1214–1225.

Nemeth, C. L., Fine, A. S. and Fatemi, A. (2019) Translational challenges in advancing regenerative therapy for treating neurological disorders using nanotechnology. *Advanced Drug Delivery Reviews*. Elsevier B.V., 148, 60–67.

Ning, X. *et al.* (2019) Longterm in vivo CT tracking of mesenchymal stem cells labeled with Au@BSA@PLL nanotracers. *Nanoscale*, 11, 20932–20941.

Oliveira, J. *et al.* (2010) Ex vivo culturing of stromal cells with dexamethasone-loaded carboxymethylchitosan/ poly(amidoamine) dendrimer nanoparticles promotes ectopic bone formation. *Bone*, 46, 1424–1435.

Park, J. (2007) In vitro and in vivo test of PEG/PCL-based hydro gel scaffold for cell delivery application. *Journal of Controlled Release*, 124, 51–59.

Park, J. S. *et al.* (2011) Chondrogenesis of human mesenchymal stem cells in fibrin constructs evaluated in vitro and in nude mouse and rabbit defects models. *Biomaterials*, 32, 1495–1507.

Park, K. *et al.* (2009) Bone morphogenic protein-2 (BMP-2) loaded nanoparticles mixed with human mesenchymal stem cell in fibrin hydrogel for bone tissue engineering. *Journal of bioscience and bioengineering*, 108, 530–537.

Patel, D. (2013) Development & screening approach for lipid nanoparticle: A review. *International Journal of Innovations in Pharmaceutical Sciences*, 2(5), 27–32.

Peters, E. (2018) Endothelial progenitor cells for the vascularization of engineered tissues. *Tissue Eng. Part B Rev*, 24, 1–24.

Pina, S. *et al.* (2019) Scaffolding strategies for tissue engineering and regenerative medicine applications. *Materials*, 12, 1824.

Popara, P. *et al.* (2018) Silica nanoparticles actively engage with mesenchymal stem cells in improving acute functional cardiac integration. *Nanomedicine*, 13, 1121–1138.

Pozo-Rodríguez, A. del *et al.* (2019) Gene therapy. *Advances in biochemical engineering/biotechnology*, 171, 321–368.

Qin, X. *et al.* (2018) Photoacoustic imaging of embryonic stem cell-derived

cardiomyocytes in living hearts with ultrasensitive semiconducting polymer nanoparticles. *Advanced Functional Materials*, 28, 1704939.

Quaglia, F. (2008) Bioinspired tissue engineering: the great promise of protein delivery technologies. *International Journal of Pharmaceutics*, 364, 281–297.

Rampichova, M. (2012) A simple drug anchoring microfiber scaffold for chondrocyte seeding and proliferation. *J. Mater. Sci. Mater. Med.*, 23, 555–563.

RaquelCosta-Almeida, Reis, R. L. and Gomes, M. E. (2019) Metabolic disease epidemics: emerging challenges in regenerative medicine. *Trends in endocrinology & metabolism*, 30, 147–149.

Ratanavaraporn, J., Juruya, H. and Tabata, Y. (2012) Local suppression of pro-inflammatory cytokines and the effects in BMP-2-induced bone regeneration. *Biomaterials*, 33, 304–320.

Rea, J. *et al.* (2009) Self assembling peptide–lipoplexes for substrate mediated gene delivery. *Acta Biomaterialia*, 5, 903–912.

Reichmuth, A. M. *et al.* (2016) mRNA vaccine delivery using lipid nanoparticles. *Therapeutic delivey*, 7, 5.

Santo, V., Sato, K., *et al.* (2012) Enhanced orthotopic bone regeneration promoted by intracellular delivery of dexamethasone. *J Tissue Eng Regen Med*, 6, 330.

Santo, V., Gomes, M., *et al.* (2012) From nano- to macro-scale: nanotechnology approaches for spatially controlled delivery of bioactive factors for bone and cartilage engineering. *Nanomedicine*, 7, 1045–1066.

Shah, B. S. and Mao, J. J. (2011) Labeling of mesenchymal stem cells with bioconjugated quantum dots. *Methods in molecular biology*, 680, pp. 61–75.

Shi, J. *et al.* (2013) Nanoparticle delivery of the bone morphogenetic protein 4 gene to adipose derived stem cells promotes articular cartilage repair in vitro and in Vivo. *Arthrosc*, 29, 2001.

Shuai, C. *et al.* (2014) Fabrication and characterization of calcium silicate scaffolds for tissue engineering. *Journal of Mechanics in Medicine and Biology*, 14,1450049.

Sigmund, W. *et al.* (2006) Processing and structure relationships in electrospinning of ceramic fiber systems. *J. Am. Ceram. Soc.*, 89, 395–407.

Skelton, R. *et al.* (2016) Magnetic resonance imaging of iron oxide-labeled human embryonic stem cell-derived cardiac progenitors, *Stem cells translational medicine*, 5, 67–74.

Sokolova, V. and Epple, M. (2008) Inorganic nanoparticles as carriers of nucleic acids into cells. *Angewandte Chemie - International Edition*, 47,1382–1395.

Sun, C. *et al.* (2014) Intracellular tracking of single native molecules with electroporation-delivered quantum dots. *Anal chem*, 86, 11403–11409.

Sun, H. *et al.* (2020) 3D printing of calcium phosphate scaffolds with controlled release of antibacterial functions for jaw bone repair. *Materials & Design*, 189, 108540.

Sun, Y. *et al.* (2020) The Roles of nanoparticles in stem cell-based therapy for cardiovascular disease. *Front. Bioeng. Biotechnol*, 8, 947.

Tan, W. B., Jiang, S. and Zhang, Y. (2007) Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. *Biomaterials*, 28, 1565–1571.

Thomas, S. C., Harshita, P. K. M. and Talegaonkar, S. (2015) Ceramic nanoparticles: fabrication methods and applications in drug delivery. *Current pharmaceutical design*, 21, 6165–6188.

Vasita, R. and Katti, D. (2014) Growth factor-delivery systems for tissue engineering: A materials perspective. *Expert Review of Medical Devices*, 3, 29–47.

Wang, F., Lee, I. and Holmström, N. (2006) Magnetic resonance tracking of nanoparticle labelled neural stem cells in a rat's spinal cord. *Nanotechnology*, 17, 1911–1915.

Wang, G. *et al.* (2012) Bisphosphonate-decorated lipid nanoparticles designed as drug carriers for bone diseases. *J. Biomed. Mater. Res. Part A*, 100A, 684–693.

Wang, Q. *et al.* (2016) Nanomaterials promise better bone repair. *Materials Today*, 19, 451–463.

Wang, T. and Spector, M. (2009) Development of hyaluronic acid-based scaffolds for brain tissue engineering. *Acta Biomaterialia*, 5, 2371–2384.

Whittlesey, K. J. and Sheaa, L. D. (2006) Nerve growth factor expression by PLG-mediated lipofection. *Biomaterials*, 27, 2477–2486.

Wijesinghe, W. *et al.* (2020) 4 - Filler matrix interfaces of inorganic/biopolymer composites and their applications, in *Interfaces in Particle and Fibre Reinforced Composites*, pp. 95–112.

Winn, S. *et al.* (2005) Non-viral-mediated gene therapy approaches for bone repair. *Craniofac. Res.*, 8, 183–190.

Xie, X.-H. *et al.* (2010) Structural and degradation characteristics of an innovative porous PLGA/TCP scaffold incorporated with bioactive molecular icaritin. *Biomedical materials*, 5, 054109.

Yamauchi, F., Kato, K. and Iwata, H. (2005) Layer-by-layer assembly of poly(ethyleneimine) and plasmid DNA onto transparent indium-tin oxide electrodes for

temporally and spatially specific gene transfer. *Langmuir*, 21, 836–842.

Yang, F. *et al.* (2005) Electrospinning of nano/micro scale poly(L-lactic acid) aligned fibers and their potential in neural tissue engineering. *Biomaterials*, 26, 2603–2610.

Yang, F. *et al.* (2011) Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside. *Cancer Treatment Reviews*, 37, 633–642.

Yau, W. *et al.* (2012) Directing stem cell fate by controlled RNA interference. *Biomaterials*, 2608–2628.

Yilgor, P. *et al.* (2009) Incorporation of a sequential BMP-2/BMP-7 delivery system into chitosan-based scaffolds for bone tissue engineering. *Biomaterials*, 30, 3551–3559.

Zhang, S. *et al.* (2010) Polyethylenimine- PEG coated albumin nanoparticles for BMP-2 delivery. *Biomaterials*, 31, 952–963.

Zhang, S., Doschak, M. and Uludag, H. (2009) Pharmacokinetics and bone formation by BMP-2 entrapped in polyethylenimine-coated albumin nanoparticles. *Biomaterials*, 30, 5143–5145.